Exosome therapy is being explored by ReNeuron both as a potential new nanomedicine targeting cancer and as a delivery system for gene therapy treatments.
The therapies developer is exploring multiple methods of loading exosomes, both internally and on the exosome surface, in partnership with major pharmaceutical/biotechnology companies.
If the data collected from the new collaborations is positive, the company reckons it could seek potential out-licensing deals in six months or so.
Since its latest update on the platform in November, ReNeuron said it has signed a further commercial collaboration agreement with a major pharmaceutical company, focusing on the potential of its exosomes to deliver DNA strands of therapeutic genes in the brain.
It has also started another two collaborations with academic institutions in the UK and mainland Europe to consolidate previous findings on exosomes, which could lead to further studies.
The AIM-listed firm also unveiled positive early pre-clinical data, as it showed injected exosomes were efficient in delivering to multiple brain regions and in key peripheral tissues including heart, kidney and skeletal muscle.
The studies demonstrated the potential to deliver therapies at meaningful levels to a variety of tissues while also being well-tolerated.
The firm added that it has modified certain parts of proteins to allow them to better attach to the exosome, in a method that could be applied to several types of cells, broadening the reach of the candidate.
“Our exosome platform is being deployed in collaboration with commercial third parties and it is pleasing to report that these collaborations are progressing to plan, with exciting data now emerging to demonstrate the delivery potential of this technology with a range of novel therapeutic agents, targeting the brain and other tissues,” said Olav Hellebø, chief executive of ReNeuron, in a release.
Shares rose 12% to 121p on Friday morning.